Improving lung transplant success by targeting immune responses
Targeted delivery of immunosuppressive agents to the graft endothelium forthe prevention of rejection in lung transplantation
This study is looking at new ways to help lung transplant patients by creating tiny agents that can deliver important medications directly to the lungs, helping to prevent the body from rejecting the new organ and improving overall transplant success.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11091934 on NIH RePORTER |
What this research studies
This research focuses on enhancing the success of lung transplants by developing new methods to deliver immunosuppressive agents directly to the lung graft. It recognizes that lung transplants face unique immune challenges compared to other organ transplants, and aims to create nanoagents that can block harmful immune responses while simultaneously delivering necessary medications. By addressing the specific immune mechanisms involved in lung rejection, this approach seeks to improve transplant outcomes for patients. The study will involve innovative techniques to better understand and manipulate the immune environment of the transplanted lung.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with end-stage pulmonary disease who are considering or are eligible for lung transplantation.
Not a fit: Patients who are not candidates for lung transplantation or those with conditions unrelated to lung health may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the survival rates and overall outcomes for patients receiving lung transplants.
How similar studies have performed: While this approach is innovative, similar strategies targeting immune responses in other organ transplants have shown promise, suggesting potential for success in lung transplantation.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Atkinson, Carl — Northwestern University at Chicago
- Study coordinator: Atkinson, Carl
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.